- Home
- NAGE vs ACIU Comparison
NAGE vs ACIU Comparison
Compare NAGE & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | ACIU |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.0M | 247.6M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NAGE | ACIU |
|---|---|---|
| Price | $3.06 | $2.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.00 | $10.00 |
| AVG Volume (30 Days) | ★ 346.5K | 138.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.82 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $129,423,000.00 | N/A |
| Revenue This Year | $16.51 | $706.75 |
| Revenue Next Year | $14.58 | $321.13 |
| P/E Ratio | $33.44 | ★ N/A |
| Revenue Growth | ★ 29.95 | N/A |
| 52 Week Low | $2.87 | $2.10 |
| 52 Week High | $10.05 | $4.00 |
Technical Indicators
Market Signals| Indicator | NAGE | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 41.53 |
| Support Level | $2.95 | $2.13 |
| Resistance Level | $3.61 | $2.68 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 48.94 | 10.55 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.